Defending the JAMA Study on Salt: A Talk With Jan Staessen, MD, PhD

Linda Brookes, MSc


June 14, 2011

In This Article

The Best Evidence Study

Dr. Staessen is lead investigator and senior author of:
Stolarz-Skrzypek K, Kuznwtsova T, Thijs L, et al. Fatal and nonfatal outcomes, incidence of hypertension, and BP changes in relation to urinary sodium excretion. JAMA. 2011;305:1777-1785.

About the Interviewee

Jan Staessen, MD, PhD, heads the Studies Coordinating Centre, Laboratory of Hypertension, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Belgium. Dr. Staessen was the principal investigator of major clinical trials, including the Systolic Hypertension in Europe (Syst-Eur), Ambulatory blood Pressure monitoring and Treatment of Hypertension trial (APTH), and the Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) trials. In addition to being a member of the International Society of Hypertension, the European Society of Hypertension, and the European Society of Cardiology, Dr. Staessen is past chairman of the European Hypertension Society Working Group on Blood Pressure Monitoring. He is an International Fellow of the Council for High Blood Pressure Research of the American Heart Association. Dr. Staessen has been awarded the title of Doctor Honoris Causa from Jagiellonian University, Kraków, Poland. Dr. Staessen’s current research interests focus on the genetics, epidemiology, and treatment of hypertension. He is on the Steering Committee of the European InGenious Hypercare (IGHC) Network of Excellence and the European research project HyperGenes (HGN). Dr. Staessen also leads the International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) research consortium that is studying the role of ambulatory blood pressure measurement in the stratification of cardiovascular risk. In addition to having published over 680 papers in peer-reviewed journals, Dr. Staessen serves on the editorial board of several medical journals and he is Associate Editor of Hypertension for the European Heart Journal, Hypertension Research, and Blood Pressure Monitoring. He is an advisor to The Lancet.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.